Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable ...

Developed by South Korean firm Celltrion (Kosdaq: 068270), with this approval, Yuflyma is now fully interchangeable with the ...

South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Celltrion announced on the 20th that it has decided to repurchase its own shares worth approximately 100 billion won through its board of directors. The shares to be repurchased this time total ...

The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Celltrion’s YUFLYMA.

U.S. President Donald Trump signed an executive order aimed at lowering drug prices in the United States to match those in other countries, and local biotechnology corporation Celltrion noted ...

South Korean biopharmaceutical firm Celltrion announced Thursday that it has signed a second major deal with one of the top five pharmacy benefit managers in th ...

"Patients presenting with chronic diarrhea, blood in the stool, unexplained nausea and vomiting, or unexplained weight loss ...

Rory McIlroy, of Northern Ireland, watches his tee shot on the 17th hole during the third round of the PGA Championship golf ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...